A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies

Zhong Yao, Luka Drecun, Farzaneh Aboualizadeh, Sun Jin Kim, Zhijie Li, Heidi Wood, Emelissa J. Valcourt, Kathy Manguiat, Simon Plenderleith, Lily Yip, Xinliu Li, Zoe Zhong, Feng Yun Yue, Tatiana Closas, Jamie Snider, Jelena Tomic, Steven J. Drews, Michael A. Drebot, Allison McGeer, Mario Ostrowski, Samira Mubareka, James M. Rini, Shawn Owen () and Igor Stagljar ()
Additional contact information
Zhong Yao: University of Toronto
Luka Drecun: University of Toronto
Farzaneh Aboualizadeh: University of Toronto
Sun Jin Kim: University of Utah
Zhijie Li: University of Toronto
Heidi Wood: Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada
Emelissa J. Valcourt: Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada
Kathy Manguiat: Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada
Simon Plenderleith: Sunnybrook Research Institute
Lily Yip: Sunnybrook Research Institute
Xinliu Li: Department of Microbiology, Mount Sinai Hospital
Zoe Zhong: Department of Microbiology, Mount Sinai Hospital
Feng Yun Yue: University of Toronto
Tatiana Closas: Canadian Blood Services
Jamie Snider: University of Toronto
Jelena Tomic: University of Toronto
Steven J. Drews: Canadian Blood Services
Michael A. Drebot: Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada
Allison McGeer: Department of Microbiology, Mount Sinai Hospital
Mario Ostrowski: University of Toronto
Samira Mubareka: Sunnybrook Research Institute
James M. Rini: University of Toronto
Shawn Owen: University of Utah
Igor Stagljar: University of Toronto

Nature Communications, 2021, vol. 12, issue 1, 1-8

Abstract: Abstract Better diagnostic tools are needed to combat the ongoing COVID-19 pandemic. Here, to meet this urgent demand, we report a homogeneous immunoassay to detect IgG antibodies against SARS-CoV-2. This serological assay, called SATiN, is based on a tri-part Nanoluciferase (tNLuc) approach, in which the spike protein of SARS-CoV-2 and protein G, fused respectively to two different tNLuc tags, are used as antibody probes. Target engagement of the probes allows reconstitution of a functional luciferase in the presence of the third tNLuc component. The assay is performed directly in the liquid phase of patient sera and enables rapid, quantitative and low-cost detection. We show that SATiN has a similar sensitivity to ELISA, and its readouts are consistent with various neutralizing antibody assays. This proof-of-principle study suggests potential applications in diagnostics, as well as disease and vaccination management.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22102-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22102-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22102-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().